Arthritis Research Canada at EULAR 2025
June 14
The EULAR European Congress of Rheumatology is the primary platform for exchange of scientific and clinical information in Europe. It seeks to provide a forum of the highest standard for scientific, educational and social exchange between professionals involved in rheumatology. It also incorporates liaising with patient organizations in order to achieve progress in the clinical care of people with rheumatic diseases.
The EULAR Congress attracts over 18,000 delegates from more than 130 countries and takes place in a major European city. This year, the EULAR Congress will take place in Barcelona from June 11 to June 14.
To learn about Arthritis Research Canada research presented at the EULAR European Congress of Rheumatology (Day 4), please scroll down.
Reliability and validity of four global measures of presenteeism in a sample of adults with inflammatory arthritis. POS0404
This study looked at how well four short questionnaires (called global measures) capture work productivity loss (presenteeism) in people with inflammatory arthritis. The study tested these four global measures in working adults from nine countries and found that all four tools were reliable over time; however, only two – the Work Productivity and Activity Impairment Questionnaire (WPAI) and the Worker Productivity Scale-Arthritis (WPS-RA)- were closely linked to health and arthritis-related factors. These findings highlight the importance of choosing the right tool based on the specific research or clinical goal.
Research Team: Macintyre VG, Boonen A, Lacaille D, Wilkinson S, Webers C, Luquini Pereira AL, Shea B, Bosworth A, Hofstetter C, Verstappen S.
Clinical impact of signs of calcium pyrophosphate deposition disease (cppd) on radiographs of hands and wrists in a real-world cohort of patients with early rheumatoid arthritis. POS00374
This study found that approximately 1 in 5 patients with early rheumatoid arthritis showed X-ray signs suggestive of a type of arthritis related to calcium deposits in the joints, known as CPPD. These patients were typically older and had more health issues, but responded similarly to RA treatment, and they often needed stronger medications, including prednisone. This study reveals that these x-ray findings shouldn’t change the RA treatment approach for patients, but recognizing them may help guide treatment and signal a need for closer management.
Research Team: Tremblay C, Carrier N, Allard-Chamard H, Marrugo J, Roux S, Boire G, Masetto A
Sap-001, a first –in-class compound targeting a renal urate transporter, shows potent serum urate-lowering effects and favorable safety profile in a US phase 2b study in patients with refractory gout with or without palpable tophi. LB0008
SAP-001, a new type of oral gout medication, safely and effectively lowered uric acid levels in patients who didn’t respond to standard treatments. SAP-001 was well tolerated, with most side effects reported as mild, including gout flares and headaches. SAP-001 could become an important new option for people with hard-to-treat gout.
Research Team: (Consultants) Cui S, Arencibia C, Li L, Zhang Q, Wang O, Saillot JL, Peterson R, Choi HK, Saag K, Dalbeth N, Terkeltaub R, Miao W
Impact of social determinants of health on outcomes among adults with arthritis: A latent class analysis of nationally representative data from the Canadian Longitudinal Study of Aging. POS1415
This study utilized information from the Canadian Longitudinal Study of Aging, a Canadian survey, to evaluate how equity factors, such as race, sex and gender, interact to affect people living with arthritis. The study found that people with lower income, education, and social support had worse self-perceived health and more activity limitations, while people with higher socioeconomic status and strong social networks reported better overall healt
Research Team: Thomas MM, Sayre EC, Harrison M, De Vera MA.
